Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + bevacizumab + irinotecan + capecitabine
- Development stage
- Phase 2
- Lead developer
- Anhui Provincial Tumor Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Group B-Anhui Provincial Cancer Hospital-colorectal cancer refers to a specific treatment arm in a Phase II clinical trial (NCT05146102) sponsored by the Anhui Provincial Cancer Hospital. This combination therapy regimen consists of the PD-1 checkpoint inhibitor sintilimab, the anti-angiogenic VEGF inhibitor bevacizumab, and the chemotherapy agents irinotecan and capecitabine (collectively known as the CAPIRI regimen). The study specifically targets patients with advanced microsatellite stable (MSS) or proficient mismatch repair (pMMR) colorectal cancer who do not have liver metastases. The rationale for this multi-drug approach is to convert the typically 'cold' immune environment of MSS colorectal cancer into an 'immunologically hot' one by combining immunotherapy with targeted anti-angiogenic therapy and cytotoxic chemotherapy, potentially overcoming the resistance of MSS tumors to single-agent checkpoint inhibition.
- Other names
- Sintilimab + Bevacizumab + CAPIRISintilimab + Bevacizumab + Irinotecan + Capecitabine
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on sintilimab + bevacizumab + irinotecan + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + bevacizumab + irinotecan + capecitabine.